09-27-2019 - Amazon S3 · Last update: 20-06-2018 08:52:59am Term: FINAL_PROGRAMM_PDF_FOOTER_RIGHT...
Transcript of 09-27-2019 - Amazon S3 · Last update: 20-06-2018 08:52:59am Term: FINAL_PROGRAMM_PDF_FOOTER_RIGHT...
Last update: 20-06-2018 08:52:59am Term: FINAL_PROGRAMM_PDF_FOOTER_RIGHT
09-27-201914:00 - 15:30 CNS complications and management in systemic cancer patients 1
Moderation: M. Preusser, Vienna, AT
14:00 - 14:25 Cerebral edema and steroids in the era of immunotherapy
, Zürich, CHP. Roth
14:25 - 14:50 Neurological complications of immunotherapy
, Vienna, ATM. Preusser
14:50 - 15:15 Vascular complications in brain tumor patients: etiology, management and prevention
, Lille, CEDEX/FRE. Le Rhun
14:00 - 15:30 Current markers in immunotherapy 1
Moderation: S. Turajlic, London, GB
14:00 - 14:25 The clonal evolution and its impact on immunotherapy
, London, GBS. Turajlic
14:25 - 14:50 The value of PD-L1 as a biomarker beyond lung cancers
, London, GBK. Harrington
14:50 - 15:15 Targeting the microenvironment
, USW. Fridman
14:00 - 15:30 Preclinical models and imaging to guide clinical therapy 1
Moderation: S. Quezada, London, London/GB
14:00 - 14:25 Imaging of the immune system
14:25 - 14:50 Mouse models to study cancer immunology
, London, London/GBS. Quezada
14:50 - 15:15 Ex-vivo and 3D models: From mice to men
Last update: 20-06-2018 08:52:59am Term: FINAL_PROGRAMM_PDF_FOOTER_RIGHT
14:00 - 15:30 Special clinical scenarios in management of advanced melanoma 1
Moderation: P. Lorigan, Manchester, GB
14:00 - 14:25 Checkpoint inhibitors in special populations
, North Sydney, AUA. Menzies
14:25 - 14:50 When can we stop immunotherapy in patients with clinical benefit?
, Essen, DED. Schadendorf
14:50 - 15:15 What is the current systemic approach in poor prognostic advanced melanomas?
, Manchester, GBP. Lorigan
14:15 - 15:15 Multidisciplinary management of germline and somatic gene alterations in patients with metastaticbreast cancer
1
Moderation: J. Balmana, Barcelona, ES
14:15 - 14:30 Complex management of germline BRCA associated breast cancer
, Jerusalem, ILS. Paluch-Shimon
14:30 - 14:45 Germline testing: Who should we test and for what?
14:45 - 15:00 DNA repair mutations beyond germline BRCA: Do they matter for patient management? (somatic vs.
germline testing)
, Barcelona, ESJ. Balmana
14:15 - 15:15 Practical use of liquid biopsy for advanced NSCLC 1
14:15 - 14:25 Presentation by expert
, Singapore, SGD.S.W. Tan
14:25 - 15:15 Discussion led by Chair
, Lyon, CEDEX/FRM. Perol
14:15 - 15:15 SCLC: Is it time for novel therapies? 1
14:15 - 14:25 Presentation by expert
, New York, USC. Rudin
14:25 - 15:15 Discussion led by Chair
, Manchester, GBF. Blackhall
Last update: 20-06-2018 08:52:59am Term: FINAL_PROGRAMM_PDF_FOOTER_RIGHT
16:00 - 17:30 Innate immune system and anti-mitotic agents: Two fields getting together 1
16:00 - 16:20 Neutrophils and metastasis
16:20 - 16:40 Microphages and cancer
16:40 - 17:00 Micronucleation and taxanes
17:00 - 17:05 Introduction
17:05 - 17:10 Conclusions and perspectives
17:10 - 17:30 Modelling chromothripsis
16:00 - 17:30 Frontline in mRCC: Ready to select treatment? 1
Moderation: C. Porta, Pavia, IT
16:00 - 16:25 How to select patients for immunotherapy doublet
, Pavia, ITC. Porta
16:25 - 16:50 Biomarker in RCC: Clinical perspective
, Boston, UST. Choueiri
16:50 - 17:15 How to select patients for immunotherapy + VEGF inhibition
, Villejuif, CEDEX/FRL. Albiges
16:00 - 17:30 The clinical utility of analysing circulating tumor DNA in patients with colorectal cancer (CRC) 1
Moderation: T. Yoshino, Kashiwa, Chiba/JP
16:00 - 16:25 Methodological principles and current technological advances
, Graz, ATM. Speicher
16:25 - 16:50 Ongoing pivotal trials using liquid biopsy
, Kashiwa, Chiba/JPT. Yoshino
16:50 - 17:15 Potential clinical utility of analysing circulating tumor DNA for CRC
, USC. Montagut
Last update: 20-06-2018 08:52:59am Term: FINAL_PROGRAMM_PDF_FOOTER_RIGHT
16:15 - 17:15 Combination and sequence in advanced melanoma 1
16:15 - 17:05 Discussion led by Chair
, Villejuif, FRC. Robert
17:05 - 17:15 Presentation by expert
, USB. Chmielowski
16:15 - 17:15 Partial breast radiation therapy: Which patients, when, and with what technique? 1
16:15 - 16:25 Presentation by expert
, Paris, FRP. Poortmans
16:25 - 17:15 Discussion led by Chair
, Cambridge, GBC. Coles
09-28-201908:30 - 10:00 Beyond initial radical treatment of patients with lung cancer 1
08:30 - 08:35 Introduction
08:35 - 08:55 Role of imaging follow-up (include second cancers)
, Besançon, CEDEX/FRV. Westeel
08:55 - 09:15 Active management of patient’s comorbidities LH including cardiac toxicity
, Maastricht, NLA. Dingemans
09:15 - 09:35 Patient perspective/expectations
, Bern, CHR. Ihlen
09:35 - 09:55 Role of patient reported outcome in patients' follow-up
, Chapel Hill, NY/USE. Basch
09:55 - 10:00 Conclusions and perspectives
, Brussels, BET. Berghmans
Last update: 20-06-2018 08:52:59am Term: FINAL_PROGRAMM_PDF_FOOTER_RIGHT
08:30 - 10:00 Next challenges for cancer immunotherapy 1
Moderation: A. Marabelle, Villejuif, FR
08:30 - 08:50 Cell therapies
, Epalinges, CHG. Coukos
08:50 - 09:10 Turning cold into hot tumours
, Villejuif, FRA. Marabelle
09:10 - 09:10 Introduction
, Villejuif, FRA. Marabelle
09:10 - 09:30 Working on the microbiome
09:30 - 09:35 Conclusions and perspectives
09:35 - 09:55 Immunotherapy for locally advanced cancer (Adjuvant and neoadjuvant?)
, Villejuif, CEDEX/FRB. Besse
08:30 - 10:00 Meeting the liquid biopsy family 1
Moderation: M. Ignatiadis, Brussels, BE
08:30 - 08:55 New frontiers: Spliced variants
, Rotterdam, NLM. Lolkema
08:55 - 09:20 The truly Pandora’s box: Exosomes
, Baltimore, USC. Rolfo
09:20 - 09:45 The famous ones: Circulating tumour cells (CTCs) and circulating free DNA (cfDNA)
, Brussels, BEM. Ignatiadis
Last update: 20-06-2018 08:52:59am Term: FINAL_PROGRAMM_PDF_FOOTER_RIGHT
08:45 - 09:45 A family with MEN1 syndrome 1
Moderation: M.E. Pavel, Erlangen, DE
08:45 - 09:00 Genetic counselling and screening
, Oxford, Oxfordshire/GBA. Grossman
09:00 - 09:15 The endocrinologist and oncologist perspective: How to manage a patient with multiple NETs
, Erlangen, DEM. Pavel
09:15 - 09:30 The surgical perspective: Who to operate on, when and to what extent
, London, GBA. Frilling
09:30 - 09:50 Presentation of index case and family history
, Oxford, Oxfordshire/GBA. Grossman
08:45 - 09:45 Challenges in advanced GIST: Are we approaching cure? 1
08:45 - 09:35 Discussion led by Chair
, Paris, CEDEX/FRS. Bonvalot
09:35 - 09:45 Presentation by expert
, Essen, DES. Bauer
08:45 - 09:45 Locally advanced rectal cancer: What is the best perioperative treatment in 2019? 1
08:45 - 09:35 Discussion led by Chair
, Barcelona, ESR. Salazar
09:35 - 09:45 Presentation by expert
, USC. Rödel
08:45 - 09:45 Tackling the treatment options in triple negative metastatic breast cancer 1
08:45 - 08:55 Presentation by expert
, Villejuif, FRS. Delaloge
08:55 - 09:45 Discussion led by Chair
, Chapel Hill, NC/USL. Carey
Last update: 20-06-2018 08:52:59am Term: FINAL_PROGRAMM_PDF_FOOTER_RIGHT
10:15 - 11:45 Biology and early diagnosis of blood malignancies 1
Moderation: L. Quintanilla Fend, US
10:15 - 10:20 Introduction
10:20 - 10:40 Early diagnosis of secondary myeloid malignancies
, Rehovot, ILL. Shlush
10:40 - 11:00 Early lesions in haematological neoplasms
, USL. Quintanilla Fend
11:00 - 11:20 Early molecular and computational diagnostics by liquid biopsies
, USD. Rossi
11:20 - 11:40 Clonal evolution in lymphoma
, USJ. Fitzgibbon
11:40 - 12:00 Conclusions and perspectives
, USL. Quintanilla Fend
10:15 - 11:45 Next immunotherapy strategies for lung cancer 1
Moderation: M.C. Garassino, Milan, IT
10:15 - 10:35 Bispecific agents and other checkpoint inhibitors
, Milan, ITM.C. Garassino
10:35 - 10:55 Personalised vaccines
10:55 - 11:00 Conclusions and perspectives
11:00 - 11:20 Bridging the gut microbiome and immune response in lung cancer
11:20 - 11:40 Cell therapy in thoracic tumours
, USG. Dotti
11:40 - 12:00 Introduction
, Milan, ITM.C. Garassino
Last update: 20-06-2018 08:52:59am Term: FINAL_PROGRAMM_PDF_FOOTER_RIGHT
10:15 - 11:45 Precision medicine in melanoma therapy 1
Moderation: P.A. Ascierto, Napoli, IT
10:15 - 10:35 Prediction of resistance to targeted therapies
, Amsterdam, NLC. Blank
10:35 - 10:55 Prediction of resistance to immunotherapy
, Los Angeles, CA/USA. Ribas
10:55 - 11:15 Prediction of toxicity of immunotherapy
, Villejuif, FRC. Robert
11:15 - 11:20 Conclusions and perspectives
11:20 - 11:40 Who are the long-term responders to immunotherapy and targeted therapy?
, Napoli, ITP. Ascierto
11:40 - 12:00 Introduction
, Napoli, ITP. Ascierto
10:15 - 11:45 Pushing forward with immunotherapy in upper GI cancers 1
Moderation: M. Moehler, Mainz, DE
10:15 - 10:35 Conclusions and perspectives
, Mainz, DEM. Moehler
10:35 - 10:55 Overview of the current landscape of immunotherapy in upper GI cancers
, Mainz, DEM. Moehler
10:55 - 11:00 Introduction
, Nagoya, Aichi/JPK. Muro
11:00 - 11:20 Combination strategies: Primary tumour location specific or agnostic
, Nagoya, Aichi/JPK. Muro
11:20 - 11:40 Tackling resistance mechanisms as a priority
, Dundee, Scotland/GBR. Petty
11:40 - 12:00 Precision immunotherapy: Biomarker and patient selection
, New York, NY/USY. Janjigian
Last update: 20-06-2018 08:52:59am Term: FINAL_PROGRAMM_PDF_FOOTER_RIGHT
10:30 - 11:30 WHO grade II and III gliomas: State of the art management 1
Moderation: A.S. Berghoff, Vienna, AT
10:30 - 10:45 Proton therapy for low grade gliomas
, Villejuif, FRF. Dhermain
10:45 - 11:00 Diagnostics and molecular pathology: IDHwt and other subgroups
, USF. Sahm
11:00 - 11:15 Survivorship and delayed effects
, Vienna, ATA.S. Berghoff
11:15 - 11:35 Presentation of case/condition
, Vienna, ATA.S. Berghoff
10:30 - 11:30 Biomarkers for patient selection for checkpoint inhibitors in HNSCC: Where do we stand? 1
10:30 - 10:40 Presentation by expert
, Chicago, IL/UST. Seiwert
10:40 - 11:30 Discussion led by Chair
, Athens, GRA. Psyrri
10:30 - 11:30 How to sequence treatment in platinum-sensitive relapsed ovarian cancer 1
10:30 - 10:40 Presentation by expert
, Napoli, ITS. Pignata
10:40 - 11:30 Discussion led by Chair
, Houston, TX/USR. Coleman
10:30 - 11:30 Metastasis, dormancy and late recurrence 1
10:30 - 10:40 Presentation by expert
, München, DEC. Klein
10:40 - 11:30 Discussion led by Chair
Last update: 20-06-2018 08:52:59am Term: FINAL_PROGRAMM_PDF_FOOTER_RIGHT
10:30 - 11:30 Radiopharmaceuticals to treat lethal prostate cancer 1
10:30 - 10:40 Presentation by expert
, Sutton, GBC. Parker
10:40 - 11:30 Discussion led by Chair
, Athens, Attiki/GRA. Bamias
12:00 - 12:45 HPV vaccination for everybody? 1
12:00 - 12:45 HPV vaccination for everybody?
, London, GBJ. Cuzick
15:00 - 16:30 Optimal delivery of immuno-oncology (IO) in advanced NSCLC 1
Moderation: S. Peters, Lausanne, CH
15:00 - 15:20 Biomarkers for IO: Can we and should we?
, Lausanne, CHS. Peters
15:20 - 15:40 Optimal combination for first-line NSCLC
, Grosshansdorf, DEM. Reck
15:40 - 15:45 Introduction
15:45 - 16:05 Can we combine radiotherapy with IO?
16:05 - 16:25 Challenging IO after toxicity or resistance
, Villejuif, CEDEX/FRB. Besse
16:25 - 16:45 Conclusions and perspectives
, Lausanne, CHS. Peters
Last update: 20-06-2018 08:52:59am Term: FINAL_PROGRAMM_PDF_FOOTER_RIGHT
15:00 - 16:30 Novel therapeutic strategies in ABC: Immunotherapy, Antibody Drug Conjugates (ADCs) and beyond 1
Moderation: G. Curigliano, Milan, IT
15:00 - 15:25 HER2 overexpressing breast cancer
, Melbourne, VIC/AUS. Loi
15:25 - 15:50 DNA Repair strategies: Beyond PARP inhibition
15:50 - 16:15 Triple negative breast cancer (TNBC)
, Milan, ITG. Curigliano
15:00 - 16:30 Treating endometrial cancer in the molecular age 1
Moderation: M.R. Mirza, Copenhagen, DK
15:00 - 15:25 Has molecular classification changed the surgical approach in endometrial cancer?
, Innsbruck, ATC. Marth
15:25 - 15:50 Endometrial cancer enters the immunotherapy era
, Copenhagen, DKM.R. Mirza
15:50 - 16:15 Has molecular classification changed the medical approach in endometrial cancer?
, Leiden, NLC. Creutzberg
15:15 - 16:15 Is randomisation of clinical trials still the gold standard? 1
15:15 - 15:30 Why we need randomization
, Athens, Attica/GRU. Dafni
15:30 - 15:45 How non-randomized studies can lead to registration
, Villejuif, CEDEX/FRC. Massard
15:45 - 16:00 The voice of the Regulator (EMA)
, London, GBF. Pignatti
16:00 - 16:05 Presentation of case/condition: Review of novel agents licensed for use in the 21st century
Last update: 20-06-2018 08:52:59am Term: FINAL_PROGRAMM_PDF_FOOTER_RIGHT
15:15 - 16:15 Managing the frail patients 1
15:15 - 15:30 Data from geriatricians and others on the positive outcomes after proper evaluation
, Zeist, HL/NLM. Hamaker
15:30 - 15:45 Prehabilitation: The impact in surgery and medical oncology
, USS. Rostoft
15:45 - 16:00 Defining tolerability of immuno-oncology in frail patients
, Manchester, GBF. Gomes
16:45 - 18:15 Treatment of the primary tumour in the metastatic setting 1
16:45 - 17:05 The radiation perspective: Bladder carcinoma model
, Birmingham, GBN. James
17:05 - 17:25 The medical oncologist perspective
, Milan, ITA. Necchi
17:25 - 17:45 Biological rationale for treating the primary tumour
, London, GBC. Swanton
17:45 - 17:50 Presentation of case/condition
17:50 - 18:10 The urologist perspective: The RCC model
, Amsterdam, NLA. Bex
Last update: 20-06-2018 08:52:59am Term: FINAL_PROGRAMM_PDF_FOOTER_RIGHT
16:45 - 18:15 The even rarer sarcomas: Treating the untreatable 1
16:45 - 17:05 Clinical trials for the ultra-rare cancers: The regulator’s perspective
17:05 - 17:25 The pathologist's point of view: Methodology to make a difference
, USH. Schildhaus
17:25 - 17:45 Offering treatment without evidence - and financial coverage
, Milan, ITS. Stacchiotti
17:45 - 18:05 "Rare sarcoma is pants”: Help and comfort through new media
18:05 - 18:10 Introduction: Why differentiation matters
16:45 - 18:15 Challenges in the management of luminal ER + MBC 1
Moderation: F. Cardoso, Lisbon, PT
16:45 - 17:10 Management options after progression on CDK 4/6 inhibitors
, Prato, PO/ITA. di Leo
17:10 - 17:35 Mutation directed therapy for ER + breast cancer
, Houston, USM. Ellis
17:35 - 18:00 Addressing optimal first line therapy options in luminal ABC (endocrine alone vs. endocrine + targeted vs.
chemotherapy) (endocrine alone vs. endocrine + targeted vs. chemotherapy)
, Lisbon, PTF. Cardoso
Last update: 20-06-2018 08:52:59am Term: FINAL_PROGRAMM_PDF_FOOTER_RIGHT
16:45 - 18:15 Pancreatic cancer: Where are we now and where are we going? 1
16:45 - 17:05 Locally advanced disease: Drugs alone or considered addition of radiotherapy
, Modena, ITS. Cascinu
17:05 - 17:25 Can we be more precise in peri-operative therapy?
, Villejuif, CEDEX/FRM. Ducreux
17:25 - 17:45 New targets on the horizon: Integrating genomics with tumour microenvironment
, New York, NY/USE. O'Reilly
17:45 - 18:05 Molecular profiling of pancreatic cancer in guiding tumour biology understanding and drug target
discovery
, Bearsden, GBA. Biankin
09-29-201908:30 - 10:00 DNA damage response modification as a therapeutic strategy in head and neck cancer 1
Moderation: I. Braña Garcia, Barcelona, ES
08:30 - 08:50 Clinical trials of ATR inhibition
, London, GBM. Dillon
08:50 - 09:10 Nucleic acid sensing as a driver of tumour immunogenicity
09:10 - 09:30 Synthetic lethal approaches to enhancing chemotherapy and radiotherapy
, Villejuif, FRE. Deutsch
09:30 - 09:35 Conclusions and perspectives
09:35 - 09:55 Windows of opportunity studies and basket trials on DNA damage modifiers
, Barcelona, ESI. Braña Garcia
09:55 - 10:15 Introduction
, Barcelona, ESI. Braña Garcia
Last update: 20-06-2018 08:52:59am Term: FINAL_PROGRAMM_PDF_FOOTER_RIGHT
08:30 - 10:00 Molecular tumour board: Where do we stand? What’s next? 1
08:30 - 08:50 Tissue and liquid biopsies with MTB for phase 1 trial selection: Experience in the TARGET trial
, Manchester, GBM. Krebs
08:50 - 09:10 Liquid biopsy for diagnostic and longitudinal tracking of metastatic patients
, USG. Siravegna
09:10 - 09:30 Building of a comprehensive clinical and molecular genomics database for patients with
treatment-refractory cancers enrolled in clinical trials
09:30 - 09:50 Personalized oncogenomics: Is a precision approach necessary for every cancer, or is there a
therapy-driven bottleneck?
, Vancouver, British Columbia/CAD. Huntsman
08:30 - 10:00 Stratified treatment in metastatic colorectal cancer 1
Moderation: C. Koehne, Oldenburg, DE
08:30 - 08:30 Immunotherapy: Microsatellite instability high (MSI-H), microsatellite instability low (MSI-L)
, Oldenburg, DEC. Koehne
08:30 - 08:50 New models for colon cancer in preclinical research
, Glasgow, GBO. Sansom
08:50 - 09:10 RAS, BRAF and HER2 status
, Milan, ITS. Siena
09:10 - 09:15 Conclusions and perspectives
, Candiolo, (TO)/ITL. Trusolino
09:15 - 09:35 New molecular stratification
, Barcelona, ESR. Dienstmann
Last update: 20-06-2018 08:52:59am Term: FINAL_PROGRAMM_PDF_FOOTER_RIGHT
08:45 - 09:45 Toxicity profiling of immunotherapy of cancer 1
Moderation: J.B.A.G. Haanen, Amsterdam, NL
08:45 - 08:50 Presentation of case/condition
, Amsterdam, NLJ. Haanen
08:50 - 08:55 Presentation of case/condition
, Amsterdam, NLJ. Haanen
08:55 - 09:10 Managing patients with irAEs unresponsive to corticosteroids
, USC. Ribi
09:10 - 09:25 Life threatening immune toxicities
, Villejuif, CEDEX/FRS. Champiat
08:45 - 09:45 Early diagnosis of neuroendocrine tumours (NETs): Increasing awareness and optimising diagnosticwork up
1
08:45 - 08:55 Presentation by expert
, USC. Toumpanakis
08:55 - 09:45 Discussion led by Chair
, Uppsala, SEK. Oeberg
08:45 - 09:45 Specificity of upper tract urothelial carcinoma biology and management 1
08:45 - 09:35 Discussion led by Chair
, Madrid, ESJ. Puente
09:35 - 09:45 Presentation by expert
, Berlin, DEM. De Santis
Last update: 20-06-2018 08:52:59am Term: FINAL_PROGRAMM_PDF_FOOTER_RIGHT
10:15 - 11:45 Glioblastoma treatment: Where should the future lead? 1
Moderation: N. Andratschke, Zürich, CH
10:15 - 10:35 Improving by combining old agents?
, USU. Herrlinger
10:35 - 10:55 Cancer stem cells: Are they a valid therapeutic target?
, Luxembourg, LUS. Niclou
10:55 - 11:00 Introduction
11:00 - 11:05 Conclusions and perspectives
11:05 - 11:25 Antibody drug conjugates in neuro-oncology: A new road?
, Rotterdam, NLM. van den Bent
11:25 - 11:45 New developments in radiation oncology: Promise and limitations
, Zürich, CHN. Andratschke
10:15 - 11:45 Tackling the diversity of triple negative early breast cancer (TNBC) 1
Moderation: V. Dieras , R. Dent ; Rennes, CEDEX 5/FR, Singapore, SG1 2 1 2
10:15 - 10:30 Getting to grips with the biology of TNBC
, Berlin, DEC. Denkert
10:30 - 10:45 Should we incorporate immunotherapy in early breast cancer?
, Singapore, SGR. Dent
10:45 - 11:00 PARP inhibitors and DNA - damaging cytotoxic
, Rennes, CEDEX 5/FRV. Dieras
11:00 - 11:15 Future directions in TNBC early breast cancer trials
, Neu-Isenburg, DES. Loibl
11:15 - 11:20 Introduction
11:20 - 11:30 Conclusions and perspectives
11:30 - 11:45 Neoadjuvant vs adjuvant approaches in early TNBC
, Barcelona, ESJ. Cortes Castan
Last update: 20-06-2018 08:52:59am Term: FINAL_PROGRAMM_PDF_FOOTER_RIGHT
10:15 - 11:45 DNA repair: From basic science to the clinic and back 1
Moderation: T. Helleday, Stockholm, SE
10:15 - 10:40 Exploiting DNA-repair vulnerabilities in cancer therapy
, USS. Jackson
10:40 - 11:05 MTHFD2 as a target in leukemia
, Stockholm, SET. Helleday
11:05 - 11:30 DNA repair enzymes as anti-cancer drug targets
10:15 - 11:45 Genomic tumour boards towards delivering a better prostate cancer 1
Moderation: M. Rubin, New York, US/US
10:15 - 10:15 Conclusions and perspectives
, Barcelona, ESJ. Mateo
10:15 - 10:20 Introduction
10:20 - 10:40 How genomic data can result in the better delivery of prostate cancer care and research
, London, GBJ. de Bono
10:40 - 11:00 Homogenising genomic reports: What clinicians need to know
, New York, US/USM. Rubin
11:00 - 11:20 Setting up genomic tumour boards: What can be done and what needs to be done?
, Ann Arbor, USS. Tomlins
11:20 - 11:40 Managing incidental germline findings: Ethical and practical challenges
, Sutton, Surrey/GBR. Eeles
Last update: 20-06-2018 08:52:59am Term: FINAL_PROGRAMM_PDF_FOOTER_RIGHT
10:30 - 11:30 Defining optimal response in myeloma 1
Moderation: J. San Miguel, Salamanca, ES
10:30 - 10:45 Imaging
, London, GBS. Barrington
10:45 - 11:00 Haematology
, Salamanca, ESJ. San Miguel
11:00 - 11:15 Molecular biology
, Toulouse, FRH. Avet-Loiseau
11:15 - 11:35 Presentation of case/condition
, Salamanca, ESJ. San Miguel
10:30 - 11:30 Oligorecurrent and oligoprogressive NSCLC 1
10:30 - 10:45 The medical oncologist’s perspective
, London, GBM. O'Brien
10:45 - 11:00 The surgeon’s perspective
, Terrassa, Barcelona/ESR. Rami-Porta
11:00 - 11:15 The radiotherapist’s perspective
, Amsterdam, NLS. Senan
11:15 - 11:20 Presentation of case/condition
10:30 - 11:30 Radiation-associated sarcoma 1
Moderation: R.L. Haas, Amsterdam, NL
10:30 - 10:45 Our profession’s worst nightmare
, Amsterdam, NLR.L. Haas
10:45 - 11:00 Contemplating being a fisherman
11:00 - 11:15 The chameleon of chameleons: The good, the bad and the most challenging
, Boston, MA/USS. George
Last update: 20-06-2018 08:52:59am Term: FINAL_PROGRAMM_PDF_FOOTER_RIGHT
10:30 - 11:30 How to choose between single agent and combination immunotherapy 1
10:30 - 10:40 Presentation by expert
, Pamplona, ESI. Melero
10:40 - 11:30 Discussion led by Chair
, Amsterdam, NLJ. Haanen
10:30 - 11:30 Improving the outcomes from anal cancer treatment: Radiotherapy strategies and systemic therapies 1
10:30 - 10:40 Presentation by expert
, Munich, DED. Modest
10:40 - 11:30 Presentation by expert
, Leeds, GBD. Sebag-Montefiore
11:30 - 11:50 Discussion led by Chair
, Leeds, GBD. Sebag-Montefiore
12:00 - 12:45 Ras signalling and cancer 1
12:00 - 12:45 Ras signalling and cancer
, USD. Bar-Sagi
Last update: 20-06-2018 08:52:59am Term: FINAL_PROGRAMM_PDF_FOOTER_RIGHT
15:00 - 16:30 Recent advances in thyroid cancer 1
15:00 - 15:20 Targeted therapy in thyroid cancer (including anaplastic): Current standards and emerging novel
therapeutics
, Barcelona, ESJ. Capdevila
15:20 - 15:40 State of the art management of medullary thyroid cancer
15:40 - 15:45 Conclusions and perspectives
15:45 - 16:05 Insights in the biology and pathological diagnosis of thyroid malignancies
16:05 - 16:25 Tumour growth rate as a driver to commence treatment with TKI in RA-refractory differentiated thyroid
carcinoma
16:25 - 16:30 Introduction
15:00 - 16:30 Update on novel therapies in ovarian cancer 1
Moderation: J.A. Ledermann, London, London/GB
15:00 - 15:20 Do we already have biomarkers that may predict response and/or resistance to PARP inhibitors?
, Edinburgh, GBC. Gourley
15:20 - 15:40 Rationale for, and an orientation to, immunotherapy
, Lausanne, CHL. Kandalaft
15:40 - 16:00 Where do we stand with PARP inhibitors in ovarian cancer treatment in 2019
, London, London/GBJ. Ledermann
16:00 - 16:05 Conclusions and perspectives
, Barcelona, ESA. Oaknin
16:05 - 16:25 Results of immunotherapy trials in ovarian cancer: Where do we stand in 2019?
, Madrid, ESA. González Martín
Last update: 20-06-2018 08:52:59am Term: FINAL_PROGRAMM_PDF_FOOTER_RIGHT
15:00 - 16:30 Where will future technologies take us in metastatic breast cancer? 1
Moderation: J.S. Reis-Filho , F. André ; New York, NY/US, Villejuif, FR1 2 1 2
15:00 - 15:20 The role of artificial intelligence (AI)
, Gif Sur Yvette, FRN. Paragios
15:20 - 15:40 Targeting novel pathways in breast cancer
, New York, NY/USJ. Reis-Filho
15:40 - 15:45 Introduction
15:45 - 15:50 Conclusions and perspectives
15:50 - 16:10 Where are we with liquid biopsies in breast cancer?
, London, GBN. Turner
16:10 - 16:30 Next generation sequencing trials in metastatic breast cancer (ARTEMIS, AURORA, TAPUR, etc..)
(ARTEMIS, AURORA, TAPUR, etc
, Villejuif, FRF. André
15:00 - 16:30 Immunotherapy in thoracic malignancies: What has been achieved in 2019? 1
Moderation: A. Curioni, Zurich, CH
15:00 - 15:25 Does radiotherapy still have a role in stage III NSCLC in the era of immunotherapy? The radiotherapist’s
view
, USK. Franks
15:25 - 15:50 Does surgery still have a role in stage III NSCLC in the era of immunotherapy? The surgeon’s view
, Nijmegen, NLA. Verhagen
15:50 - 16:15 Where is immunotherapy for small cell lung cancer and mesothelioma now?
, Zurich, CHA. Curioni
Last update: 20-06-2018 08:52:59am Term: FINAL_PROGRAMM_PDF_FOOTER_RIGHT
15:00 - 16:30 The past year in sarcoma: Impact on clinical practice 1
Moderation: R.L. Jones, London, WA/GB
15:00 - 15:25 Metastatic soft tissue sarcoma
, London, WA/GBR. Jones
15:25 - 15:50 Bone sarcoma
, London, GBJ. Whelan
15:50 - 16:15 Primary soft tissue sarcoma
, Milan, ITA. Gronchi
15:00 - 16:30 Treatment developments in viral-associated HN malignancies 1
Moderation: A.T.C. Chan, Shatin, HK
15:00 - 15:25 EBV monitoring in nasopharyngeal Carcinoma: Staging, prognosis, treatment adaptation
, Shatin, HKA. Chan
15:25 - 15:50 Treatment de-escalation in HPV-related oropharyngeal cancer: Where do we stand?
, Lausanne, CHC. Simon
15:50 - 16:15 HPV monitoring in HPV-related oropharyngeal cancer
, USS. Bhide
15:15 - 16:15 Overcoming symptom burden in upper GI cancer 1
15:15 - 16:45 Presentation of case/condition: Jaundice
, London, GBS. Pereira
16:45 - 18:15 Presentation of case/condition: Peritoneal carcinomatosis
, USP. Piso
18:15 - 19:45 Presentation of case/condition: Pain control
, Lausanne, CHA. Wagner
19:45 - 21:15 Presentation of case/condition: Dysphagia
, Villejuif, CEDEX/FRL. Antonin
Last update: 20-06-2018 08:52:59am Term: FINAL_PROGRAMM_PDF_FOOTER_RIGHT
15:15 - 16:15 Perioperative therapy in melanoma 1
15:15 - 15:30 Neoadjuvant treatment
, North Sydney, NSW/AUG. Long
15:30 - 15:35 Presentation of case/condition
15:35 - 15:50 The role of surgery
, Amsterdam, NLA. van Akkooi
15:50 - 16:05 Adjuvant therapy: How to wisely choose the treatment and for whom
, Villejuif, FRA. Eggermont
15:15 - 16:15 Personalized cancer vaccines: A mainstay for future cancer therapy? 1
15:15 - 15:25 Presentation by expert
15:25 - 16:15 Discussion led by Chair
, USI. Dikic
16:45 - 18:15 Management of body resources in patients with advanced cancer 1
Moderation: S. Kaasa, Oslo, NO
16:45 - 17:10 Determinants of malnutrition and sarcopenia
, Edmonton, CAV. Baracos
17:10 - 17:35 Issues the clinician faces in order to apply these guidelines
, Oslo, NOS. Kaasa
17:35 - 18:00 Applying ESMO and ESPEN Guidelines: Acting before cachexia hits
, Freiburg, DEJ. Arends
Last update: 20-06-2018 08:52:59am Term: FINAL_PROGRAMM_PDF_FOOTER_RIGHT
16:45 - 18:15 Progress in the management of non-melanoma skin cancers 1
Moderation: R. Dummer, Zurich, CH
16:45 - 17:10 Update on basal cell carcinoma
, Zurich, CHR. Dummer
17:10 - 17:35 Squamous cell carcinoma
, Kiel, Schleswig-Holstein/DEA. Hauschild
17:35 - 18:00 New therapies for Merkel cell carcinoma
, Essen, DEJ. Becker
17:00 - 18:00 Liquid biopsies, tumour dormancy and minimal residual disease detection 1
17:00 - 17:15 Technical validity
17:15 - 17:30 Monitoring minimal residual disease in colorectal cancer
17:30 - 17:45 Metastases, dormancy and later recurrences
17:45 - 18:05 Presentation of case/condition
09-30-2019
Last update: 20-06-2018 08:52:59am Term: FINAL_PROGRAMM_PDF_FOOTER_RIGHT
08:30 - 10:00 Survivor care in the times of innovative therapies 1
08:30 - 08:50 Rehabilitation decreases impact of cancer on patient and society
, USN. Barizien
08:50 - 09:10 Sexuality: Practical counselling
09:10 - 09:30 Fighting fatigue: Evidence and folkore
, Montreal, CAA. Vigano
09:30 - 09:50 Lessons from pediatric oncology
, USG. Armstrong
09:50 - 10:10 Introduction
08:30 - 10:00 Targeting tumour metabolism to impact outcome from prostate cancers 1
Moderation: A. Alimonti , P.P. Pandolfi ; Bellinzona, CH, Boston, MA/US1 2 1 2
08:30 - 08:35 Conclusions and perspectives
, Bellinzona, CHA. Alimonti
08:35 - 08:55 Polyamine metabolism in prostate cancer
, Derio, ESA. Carracedo Perez
08:55 - 09:00 Introduction
09:00 - 09:20 Genetics of lipid metabolism in prostate cancer
, Boston, MA/USP.P. Pandolfi
09:20 - 09:40 Targeting immunometabolism for cancer therapy
09:40 - 10:00 Metabolic requirements of prostate cancer
, Bellinzona, CHA. Alimonti
Last update: 20-06-2018 08:52:59am Term: FINAL_PROGRAMM_PDF_FOOTER_RIGHT
08:30 - 10:00 Management of lymphomas in light of the updated WHO classification 1
Moderation: M. Trneny, Prague, 2/CZ
08:30 - 08:55 Aggressive B-cell lymphomas
, Prague, 2/CZM. Trneny
08:55 - 09:20 T-cell lymphomas
, Aarhus C, DKF. D'Amore
09:20 - 09:45 Indolent B-cell lymphomas
, London, GBS. Montoto
08:45 - 09:45 Treating young patients with BRCA-mutated early breast cancers 1
Moderation: O. Gentilini, US
08:45 - 09:00 Tailoring radiation treatment in patients with BRCA mutated tumours
, USB. Offersen
09:00 - 09:15 Preserving fertility in young women receiving adjuvant chemotherapy
, Boston, USA. Partridge
09:15 - 09:20 Presentation of case/condition
09:20 - 09:35 Caveats in surgical decision-making in patients with BRCA mutated tumours
, USO. Gentilini
08:45 - 09:45 Are big data, deep learning and AI methods changing cancer care and research? 1
08:45 - 09:00 Presentation by expert
, USB. Al-Lazikani
09:00 - 09:15 Presentation by expert
, Rotterdam, NLS. Sleijfer
09:15 - 09:35 Discussion led by Chair
, Rotterdam, NLS. Sleijfer
Last update: 20-06-2018 08:52:59am Term: FINAL_PROGRAMM_PDF_FOOTER_RIGHT
08:45 - 09:45 How do we personalize treatment in stage III NSCLC 1
08:45 - 09:35 Discussion led by Chair
, Winterthur, CHM. Pless
09:35 - 09:45 Presentation by expert
, Essen, DEW. Eberhardt
08:45 - 09:45 Is there a role for immunotherapy in gliomas? 1
08:45 - 08:55 Presentation by expert
, Zürich, CHM. Weller
08:55 - 09:45 Discussion led by Chair
, Rotterdam, NLM. van den Bent
10:15 - 11:45 Individualised dosing of commonly used anti-cancer agents 1
Moderation: E. Calvo , R.H. Mathijssen ; Madrid, ES, Rotterdam, NL1 2 1 2
10:15 - 10:30 Drug-food interactions
, Pisa, ITM. Del Re
10:30 - 10:45 Therapeutic drug monitoring (TDM) of tyrosine kinase inhibitors (TKIs)
, USM. Joerger
10:45 - 11:00 Drug-drug interactions: Focus on acid-suppressive agents
, Rotterdam, NLR. Mathijssen
11:00 - 11:15 Pharmacogenomics guided adaptive dosing of fluoropyrimidines
, Amsterdam, NLJ. Schellens
11:15 - 11:30 Optimising dosing of I-O agents
, Madrid, ESE. Calvo
11:30 - 11:50 Introduction
11:50 - 12:10 Conclusions and perspectives
Last update: 20-06-2018 08:52:59am Term: FINAL_PROGRAMM_PDF_FOOTER_RIGHT
10:15 - 11:45 Selecting and sequencing therapy in previously untreated urothelial cancer 1
Moderation: T.B. Powles, London, GB
10:15 - 10:35 Immune therapy in combination with targeted therapy
, Villejuif, FRY. Loriot
10:35 - 10:55 Biomarkers beyond PD-L1 expression to predict outcome to immune therapy
10:55 - 11:15 Immune therapy in combination with chemotherapy
, London, GBT. Powles
11:15 - 11:20 Introduction
11:20 - 11:25 Conclusions and perspectives
11:25 - 11:45 Single agent immune therapy and immune combinations
, Boston, MA/USJ. Bellmunt
10:15 - 11:45 Single cell cancer analysis 1
10:15 - 10:40 Single cell DNA sequencing and the clonal evolution of epithelial cancers
10:40 - 11:05 Technological advances in single cell technology to dissect molecular circuitry of cancer from primary to
metastasis (Perturb-Seq, DroNucseq)
11:05 - 11:30 Single cell RNA sequencing to decipher epithelial cancers and their microenvironments
, USJ. Marioni
Last update: 20-06-2018 08:52:59am Term: FINAL_PROGRAMM_PDF_FOOTER_RIGHT
10:30 - 11:30 Peritoneal metastases from colorectal cancer 1
Moderation: J. Taieb, Paris, FR
10:30 - 10:45 The surgical oncology perspective
, USB. Rau
10:45 - 11:00 The medical oncology perspective
, Paris, FRJ. Taieb
11:00 - 11:05 Presentation of case/condition
11:05 - 11:20 The pathology perspective
, Caen, CEDEX 5/FRF. Bibeau
10:30 - 11:30 Young patients with stage IB2 cervical cancer 1
10:30 - 10:45 The role of surgery: Is there a place for conservative treatment?
, Munich, DES. Mahner
10:45 - 11:00 The role of the medical treatment: Is there a place for neoadjuvant chemotherapy?
, USM. McCormack
11:00 - 11:15 The role of radiotherapy treatment: Can modern techniques reduce the burden of toxicity?
, Leiden, NLR. Nout
11:15 - 11:20 Presentation of case/condition
10:30 - 11:30 Drug interaction and the key role of kidney function in onco-haematology 1
10:30 - 11:20 Discussion led by Chair
, USB. Sprangers
11:20 - 11:30 Presentation by expert
, Paris, CEDEX 13/FRV. Launay-Vacher
12:00 - 12:45 Caloric restriction mimetics, autophagy and cancer 1
12:00 - 12:45 Caloric restriction mimetics, autophagy and cancer
, Paris, CEDEX/FRG. Kroemer
Last update: 20-06-2018 08:52:59am Term: FINAL_PROGRAMM_PDF_FOOTER_RIGHT
15:00 - 16:30 How to use the available results of precision medicine clinical trials 1
Moderation: E. Calvo, Madrid, ES
15:00 - 15:07 Introduction
15:07 - 15:22 Other platform trials of precision medicine
, Paris, FRC. Le Tourneau
15:22 - 15:37 Umbrella trials
, Oxford, GBT. Maughan
15:37 - 15:52 Including biomarkers in clinical trials: Biostatistician view
, Villejuif, FRX. Paoletti
15:52 - 16:07 Basket trials
, Leuven, BEP. Schoeffski
16:07 - 16:22 Precision medicine: Counterpoint
, Madrid, ESE. Calvo
15:00 - 16:30 Tumour neoantigens 1
Moderation: A. Bardelli, Candiolo, (TO)/IT
15:00 - 15:20 Cancer genomes and neoantigens
, Los Angeles, CA/USA. Ribas
15:20 - 15:40 From tumour antigens to HLA peptides in melanoma
, Rehovot, MD/ILY. Samuels
15:40 - 16:00 Functional basis of neopeptides immune surveillance
16:00 - 16:05 Introduction
16:05 - 16:10 Conclusions and perspectives
16:10 - 16:30 MMR repair driven neoantigens
, Candiolo, (TO)/ITA. Bardelli
Last update: 20-06-2018 08:52:59am Term: FINAL_PROGRAMM_PDF_FOOTER_RIGHT
15:00 - 16:30 The next horizon in metastatic non-small cell targeted therapy 1
Moderation: D. Planchard , L. Paz-Ares ; Villejuif, FR, Madrid, ES1 2 1 2
15:00 - 15:20 The optimal sequence: Does overall survival matter?
, Shatin, HKT.S.K. Mok
15:20 - 15:40 How to manage co-occurrence of drivers
, Madrid, ESL. Paz-Ares
15:40 - 16:00 Uncommon targets: BRAF, MET and NTRK
, Villejuif, FRD. Planchard
16:00 - 16:20 Targeted KRAS mutation
, Boston, MA/USP. Jänne
15:15 - 16:30 Options and limitations in oligometastatic disease and metastatic colorectal cancer (mCRC) 1
15:15 - 15:30 The radiation oncology perspective
, USM. Hawkins
15:30 - 15:45 The surgical perspective
, USR. Raab
15:45 - 16:00 The medical oncology perspective
, Belfast, GBR. Wilson
16:00 - 16:15 The interventional radiology perpective
, Villejuif, FRT. de Baere
15:15 - 16:15 Treatment of pelvic node-positive prostate cancer 1
15:15 - 15:30 Systemic treatment: The role of chemotherapy and androgen receptor targeted therapy
, St. Gallen, CHS. Gillessen
15:30 - 15:35 Presentation of case/condition
15:35 - 15:50 Is there a role for radical surgery?
15:50 - 16:05 Advances in pelvic nodal radiotherapy
, USG. De Meerleer
Last update: 20-06-2018 08:52:59am Term: FINAL_PROGRAMM_PDF_FOOTER_RIGHT
15:15 - 16:15 Squamous cell carcinoma of the oesophagus 1
15:15 - 16:05 Presentation by Chair
, Odense C, DKP. Pfeiffer
16:05 - 16:15 Discussion led by expert
, UST. Crosby
15:15 - 16:15 The promise of cure: Chemotherapy free therapies in CLL 1
15:15 - 15:25 Presentation by expert
15:25 - 16:15 Discussion led by Chair
, USJ. Gribben
16:45 - 18:15 Bronchial neuroendocrine tumours 1
16:45 - 17:10 The genomic landscape
, London, GBC. Thirlwell
17:10 - 17:35 Challenges in pathological and molecular classifications
, Milan, ITM. MILIONE
17:35 - 18:00 Seeking the optimal treatment sequence in advanced disease
, Clayton, NSW/AUE. Segelov
16:45 - 18:15 How to handle comorbidities in the treatment decision of stages I to III NSCLC 1
16:45 - 17:10 Other significant comorbidities
, Brussels, BET. Berghmans
17:10 - 17:35 Cardiac risk assessment
, Leeds, GBA. Brunelli
17:35 - 18:00 Pulmonary risk assessment
, Amsterdam, NLP. Baas
Last update: 20-06-2018 08:52:59am Term: FINAL_PROGRAMM_PDF_FOOTER_RIGHT
16:45 - 18:15 Optimal adjuvant and neo-adjuvant therapy in HER-2 + patients 1
Moderation: A. Prat, Barcelona, ES
16:45 - 17:10 Optimal current regimens in the adjuvant setting
, Munich, DEN. Harbeck
17:10 - 17:35 Dissecting the heterogeneity of HER2+ breast cancer
, Barcelona, ESA. Prat
17:35 - 18:00 Lessons learned and opportunities from the neo-adjuvant setting
, Chapel Hill, NC/USL. Carey
17:00 - 18:00 Precision medicine for sarcoma: Are we there yet? 1
Moderation: E. De Alava, Sevilla, ES
17:00 - 17:15 Insights from basic research
, Paris, FRO. Delattre
17:15 - 17:30 Insights from oncology
, Zerifin, ILD. Katz
17:30 - 17:45 Insights from pathology
, Sevilla, ESE. De Alava
17:45 - 18:05 Presentation of case/condition
, Zerifin, ILD. Katz
17:00 - 18:00 Treatment of locally recurrent head and neck cancers 1
17:00 - 17:05 Presentation of case/condition
17:05 - 17:20 Improving patient selection for surgical candidates
, Birmingham, West Midlands/GBH. Mehanna
17:20 - 17:35 Molecular insights into treatment decisions
, USI. Tinhofer
17:35 - 17:50 Indications for re-irradation
, Villejuif, FRP. Blanchard